Nuclear medicine practice in Japan

a report of the eighth nationwide survey in 2017

Yoshihiro Nishiyama, Seigo Kinuya, Takashi Kato, Daiki Kayano, Shuhei Sato, Manabu Tashiro, Mitsuaki Tatsumi, Teisuke Hashimoto, Shingo Baba, Kenji Hirata, Mana Yoshimura, Hiroto Yoneyama

研究成果: ジャーナルへの寄稿記事

抄録

Objective: Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. Methods: The subcommittee sent questionnaires, including the number and category of examinations as well as the kind and dose of the radiopharmaceuticals during the 30 days of June 2017, to all nuclear medicine institutes. The total numbers for the year 2017 were then estimated. Results: A total of 1132 institutes responded to the survey, including 351 PET centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1332 in total, with 7.0% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 88.2 and 23.6%, respectively. The number of single-photon tracer studies in 2017 was 1.08 million which means a decrease in 5.7% in 5 years and 23.6% in 10 years. All but neurotransmitter system, sentinel lymph node, and liver scintigraphy decreased. Bone scintigraphy was a leading examination (32.3%), followed by myocardial scintigraphy (24.1%) and cerebral perfusion study (18.0%) in order. SPECT studies showed an increase from 47.2% to 63.5%. PET centers have also increased from 295 to 389, as compared to the last survey. The 112 PET centers have installed one or two in-house cyclotrons. PET studies showed 24.5% increase in 5 years, with oncology accounting for 88.9%. 18F-FDG accounted for 98.2% (630,570 examinations). PET examinations using 11C-methionine have decreased, with 2440 examinations in 2017. PET examinations using 13N-NH3 have been increasing, with 2363 examinations in 2017. The number of PET studies using 11C-PIB was 904. 131I-radioiodine targeted therapies showed an increase in 5 years (23.1%), including 4487 patients for thyroid cancer. Out-patient thyroid bed ablation therapy with 1,110 MBq of 131I accounted for 36.6% of cancer patients. The number of admission rooms increased from 135 to 157 in 5 years. The number of 223Ra targeted therapies for castration-resistant metastatic prostate cancer was 1194 patients. Conclusions: Single-photon examinations showed a continuous tendency toward a decline in the survey. In contrast, the number of hybrid SPECT/CT scanner examinations has increased. PET/CT study and radionuclide targeted therapy have steadily increased.

元の言語英語
ジャーナルAnnals of Nuclear Medicine
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

Nuclear Medicine
Japan
Photons
Radionuclide Imaging
Cyclotrons
Gamma Cameras
Myocardial Perfusion Imaging
Radiopharmaceuticals
Castration
Fluorodeoxyglucose F18
Therapeutics
Surveys and Questionnaires
Single-Photon Emission-Computed Tomography
Thyroid Neoplasms
Radioisotopes
Methionine
Neurotransmitter Agents
Prostatic Neoplasms
Thyroid Gland
Outpatients

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

これを引用

Nuclear medicine practice in Japan : a report of the eighth nationwide survey in 2017. / Nishiyama, Yoshihiro; Kinuya, Seigo; Kato, Takashi; Kayano, Daiki; Sato, Shuhei; Tashiro, Manabu; Tatsumi, Mitsuaki; Hashimoto, Teisuke; Baba, Shingo; Hirata, Kenji; Yoshimura, Mana; Yoneyama, Hiroto.

:: Annals of Nuclear Medicine, 01.01.2019.

研究成果: ジャーナルへの寄稿記事

Nishiyama, Y, Kinuya, S, Kato, T, Kayano, D, Sato, S, Tashiro, M, Tatsumi, M, Hashimoto, T, Baba, S, Hirata, K, Yoshimura, M & Yoneyama, H 2019, 'Nuclear medicine practice in Japan: a report of the eighth nationwide survey in 2017', Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-019-01382-5
Nishiyama, Yoshihiro ; Kinuya, Seigo ; Kato, Takashi ; Kayano, Daiki ; Sato, Shuhei ; Tashiro, Manabu ; Tatsumi, Mitsuaki ; Hashimoto, Teisuke ; Baba, Shingo ; Hirata, Kenji ; Yoshimura, Mana ; Yoneyama, Hiroto. / Nuclear medicine practice in Japan : a report of the eighth nationwide survey in 2017. :: Annals of Nuclear Medicine. 2019.
@article{3eaecb1d6fe842c5898b7ca7e35e4d66,
title = "Nuclear medicine practice in Japan: a report of the eighth nationwide survey in 2017",
abstract = "Objective: Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. Methods: The subcommittee sent questionnaires, including the number and category of examinations as well as the kind and dose of the radiopharmaceuticals during the 30 days of June 2017, to all nuclear medicine institutes. The total numbers for the year 2017 were then estimated. Results: A total of 1132 institutes responded to the survey, including 351 PET centers. The recovery rate was 90.6{\%}. The number of gamma cameras installed was 1332 in total, with 7.0{\%} decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 88.2 and 23.6{\%}, respectively. The number of single-photon tracer studies in 2017 was 1.08 million which means a decrease in 5.7{\%} in 5 years and 23.6{\%} in 10 years. All but neurotransmitter system, sentinel lymph node, and liver scintigraphy decreased. Bone scintigraphy was a leading examination (32.3{\%}), followed by myocardial scintigraphy (24.1{\%}) and cerebral perfusion study (18.0{\%}) in order. SPECT studies showed an increase from 47.2{\%} to 63.5{\%}. PET centers have also increased from 295 to 389, as compared to the last survey. The 112 PET centers have installed one or two in-house cyclotrons. PET studies showed 24.5{\%} increase in 5 years, with oncology accounting for 88.9{\%}. 18F-FDG accounted for 98.2{\%} (630,570 examinations). PET examinations using 11C-methionine have decreased, with 2440 examinations in 2017. PET examinations using 13N-NH3 have been increasing, with 2363 examinations in 2017. The number of PET studies using 11C-PIB was 904. 131I-radioiodine targeted therapies showed an increase in 5 years (23.1{\%}), including 4487 patients for thyroid cancer. Out-patient thyroid bed ablation therapy with 1,110 MBq of 131I accounted for 36.6{\%} of cancer patients. The number of admission rooms increased from 135 to 157 in 5 years. The number of 223Ra targeted therapies for castration-resistant metastatic prostate cancer was 1194 patients. Conclusions: Single-photon examinations showed a continuous tendency toward a decline in the survey. In contrast, the number of hybrid SPECT/CT scanner examinations has increased. PET/CT study and radionuclide targeted therapy have steadily increased.",
author = "Yoshihiro Nishiyama and Seigo Kinuya and Takashi Kato and Daiki Kayano and Shuhei Sato and Manabu Tashiro and Mitsuaki Tatsumi and Teisuke Hashimoto and Shingo Baba and Kenji Hirata and Mana Yoshimura and Hiroto Yoneyama",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12149-019-01382-5",
language = "English",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Nuclear medicine practice in Japan

T2 - a report of the eighth nationwide survey in 2017

AU - Nishiyama, Yoshihiro

AU - Kinuya, Seigo

AU - Kato, Takashi

AU - Kayano, Daiki

AU - Sato, Shuhei

AU - Tashiro, Manabu

AU - Tatsumi, Mitsuaki

AU - Hashimoto, Teisuke

AU - Baba, Shingo

AU - Hirata, Kenji

AU - Yoshimura, Mana

AU - Yoneyama, Hiroto

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. Methods: The subcommittee sent questionnaires, including the number and category of examinations as well as the kind and dose of the radiopharmaceuticals during the 30 days of June 2017, to all nuclear medicine institutes. The total numbers for the year 2017 were then estimated. Results: A total of 1132 institutes responded to the survey, including 351 PET centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1332 in total, with 7.0% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 88.2 and 23.6%, respectively. The number of single-photon tracer studies in 2017 was 1.08 million which means a decrease in 5.7% in 5 years and 23.6% in 10 years. All but neurotransmitter system, sentinel lymph node, and liver scintigraphy decreased. Bone scintigraphy was a leading examination (32.3%), followed by myocardial scintigraphy (24.1%) and cerebral perfusion study (18.0%) in order. SPECT studies showed an increase from 47.2% to 63.5%. PET centers have also increased from 295 to 389, as compared to the last survey. The 112 PET centers have installed one or two in-house cyclotrons. PET studies showed 24.5% increase in 5 years, with oncology accounting for 88.9%. 18F-FDG accounted for 98.2% (630,570 examinations). PET examinations using 11C-methionine have decreased, with 2440 examinations in 2017. PET examinations using 13N-NH3 have been increasing, with 2363 examinations in 2017. The number of PET studies using 11C-PIB was 904. 131I-radioiodine targeted therapies showed an increase in 5 years (23.1%), including 4487 patients for thyroid cancer. Out-patient thyroid bed ablation therapy with 1,110 MBq of 131I accounted for 36.6% of cancer patients. The number of admission rooms increased from 135 to 157 in 5 years. The number of 223Ra targeted therapies for castration-resistant metastatic prostate cancer was 1194 patients. Conclusions: Single-photon examinations showed a continuous tendency toward a decline in the survey. In contrast, the number of hybrid SPECT/CT scanner examinations has increased. PET/CT study and radionuclide targeted therapy have steadily increased.

AB - Objective: Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. Methods: The subcommittee sent questionnaires, including the number and category of examinations as well as the kind and dose of the radiopharmaceuticals during the 30 days of June 2017, to all nuclear medicine institutes. The total numbers for the year 2017 were then estimated. Results: A total of 1132 institutes responded to the survey, including 351 PET centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1332 in total, with 7.0% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 88.2 and 23.6%, respectively. The number of single-photon tracer studies in 2017 was 1.08 million which means a decrease in 5.7% in 5 years and 23.6% in 10 years. All but neurotransmitter system, sentinel lymph node, and liver scintigraphy decreased. Bone scintigraphy was a leading examination (32.3%), followed by myocardial scintigraphy (24.1%) and cerebral perfusion study (18.0%) in order. SPECT studies showed an increase from 47.2% to 63.5%. PET centers have also increased from 295 to 389, as compared to the last survey. The 112 PET centers have installed one or two in-house cyclotrons. PET studies showed 24.5% increase in 5 years, with oncology accounting for 88.9%. 18F-FDG accounted for 98.2% (630,570 examinations). PET examinations using 11C-methionine have decreased, with 2440 examinations in 2017. PET examinations using 13N-NH3 have been increasing, with 2363 examinations in 2017. The number of PET studies using 11C-PIB was 904. 131I-radioiodine targeted therapies showed an increase in 5 years (23.1%), including 4487 patients for thyroid cancer. Out-patient thyroid bed ablation therapy with 1,110 MBq of 131I accounted for 36.6% of cancer patients. The number of admission rooms increased from 135 to 157 in 5 years. The number of 223Ra targeted therapies for castration-resistant metastatic prostate cancer was 1194 patients. Conclusions: Single-photon examinations showed a continuous tendency toward a decline in the survey. In contrast, the number of hybrid SPECT/CT scanner examinations has increased. PET/CT study and radionuclide targeted therapy have steadily increased.

UR - http://www.scopus.com/inward/record.url?scp=85067924827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067924827&partnerID=8YFLogxK

U2 - 10.1007/s12149-019-01382-5

DO - 10.1007/s12149-019-01382-5

M3 - Article

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

ER -